NCT01532310 - Belimumab (BENLYSTA®) Pregnancy Registry | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2012

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

belimumab

Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus

Trial Locations (15)

GSK Investigational Site, Bern

GSK Investigational Site, Liège

GSK Investigational Site, Innsbruck

GSK Investigational Site, Zurich

GSK Investigational Site, Sankt Gallen

GSK Investigational Site, Wilmington

GSK Investigational Site, Düsseldorf

GSK Investigational Site, Bilbao

GSK Investigational Site, Tel Litwinsky

GSK Investigational Site, Pisa

GSK Investigational Site, Paris

GSK Investigational Site, Wilmington

GSK Investigational Site, Québec

GSK Investigational Site, Almada

GSK Investigational Site, Stockholm